Medicines Development for Global Health (MDGH) announced today that the Ghana Food and Drugs Authority has approved moxidectin 2 mg oral tablets for the treatment of river blindness (onchocerciasis) in adults and children aged four years and older. This marks a significant step forward in the fight against this debilitating disease, with Ghana becoming the first river blindness-endemic country to grant regulatory approval for moxidectin.
This approval sets the stage for the MOMENTUM pilot program, slated to begin in January 2025 in the Twifo Atti-Morkwa district. The program represents a collaborative effort between the Ghana Health Service, the University of Health and Allied Sciences in Ghana, the Bruyère Health Research Institute in Canada, the Access and Delivery Partnership, and MDGH.
This achievement was made possible with the support of the Global Health Investment Fund (GHIF), an innovative financing mechanism that played a key role in enabling the development and delivery of moxidectin. Lion’s Head Global Partners is proud to have contributed to this initiative by creating and structuring the GHIF, helping to channel resources to this global health solution.
At Lion’s Head we are honoured to support innovative health financing solutions that facilitate the development and delivery of life-changing treatments to communities in need. This milestone reflects the power of partnerships and strategic investments to advance global health equity.
Read the full press release here and learn more about the MOMENTUM program here.
For more updates on our work and initiatives, visit our LinkedIn page and website.
